ANI Pharmaceuticals' (ANIP) Buy Rating Reaffirmed at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Guggenheim in a report issued on Monday,Benzinga reports. They presently have a $86.00 price objective on the specialty pharmaceutical company's stock. Guggenheim's price target indicates a potential upside of 44.46% from the stock's previous close.

Several other research analysts have also recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Stock Down 1.4%

ANIP stock traded down $0.84 during midday trading on Monday, reaching $59.53. The company had a trading volume of 597,425 shares, compared to its average volume of 297,360. The company has a 50 day moving average of $66.94 and a two-hundred day moving average of $60.74. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $77.00. The company has a market capitalization of $1.30 billion, a P/E ratio of -108.24 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the business posted $0.82 EPS. The business's quarterly revenue was up 43.4% on a year-over-year basis. On average, equities research analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. The trade was a 0.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This trade represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,800 shares of company stock valued at $173,976 in the last three months. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. US Bancorp DE raised its stake in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the period. National Bank of Canada FI bought a new stake in ANI Pharmaceuticals in the 1st quarter valued at about $79,000. KBC Group NV raised its stake in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the period. GAMMA Investing LLC raised its stake in ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after acquiring an additional 881 shares during the period. Finally, Mesirow Financial Investment Management Inc. bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $206,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.